AstraZeneca (LON:AZN) Price Target Raised to GBX 8,200
AstraZeneca (LON:AZN) had its target price raised by Barclays from GBX 8,000 ($104.53) to GBX 8,200 ($107.15) in a report released on Friday, Borsen Zeitung reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
Several other equities analysts also recently weighed in on AZN. Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the stock a sell rating in a research report on Monday, September 2nd. Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Citigroup reissued a buy rating and set a £100 ($130.67) price target (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research report on Wednesday, September 11th. Deutsche Bank raised their price target on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock a buy rating in a research report on Monday, September 9th. Finally, Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, August 27th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of GBX 7,050 ($92.12).
Shares of AZN stock opened at GBX 6,793 ($88.76) on Friday. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95. The stock has a fifty day moving average price of GBX 7,160.31 and a 200 day moving average price of GBX 6,398.61. The stock has a market cap of $89.12 billion and a PE ratio of 39.68. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,583 ($99.09).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Margin
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.